Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Sorry, Go hear

Re: Wolf... (from today's schedule 14A)

in response to by
posted on Apr 03, 2007 02:38PM
  

The Company’s stockholders previously approved each of the Company’s 1992, 1996, 2001, 2003 and 2006 Stock Option Plans. The following table sets forth certain information concerning aggregate stock options authorized for issuance under the Company’s 1996, 2001, 2003 and 2006 Stock Option Plans as of May 31, 2006.

Shares of common stock issuable on the exercise of warrants have not been approved by the Company’s stockholders and, accordingly, have been segregated in the table below.

Plan Category

 

Number of securities to be
issued upon exercise of
outstanding options
and warrants

 

Weighted-average
exercise price of
outstanding options
and warrants

 

Number of securities
remaining available for
future issuance under
equity compensation plans

               

Equity compensation plans approved
by security holders                                       

     

5,460,000

     

$

0.34

     

5,229,000

Equity compensation plans not approved
by security holders

 

53,349,220

 

$

0.05

 

Total

 

58,809,220

       
Share
New Message
Please login to post a reply